Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Iterum Therapeutics Plc (ITRM)
NASDAQ:ITRM
RESEARCH TOOLSreports
Holding ITRM?
Track your performance easily
ITRM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.62 - $2.50
Previous Close$1.09
Volume109.54K
Average Volume (3M)313.31K
Market Cap
$24.75M
Enterprise Value$25.98M
Total Cash (Recent Filing)$11.72M
Total Debt (Recent Filing)$12.95M
Price to Earnings (P/E)―
Beta2.59
Next Earnings
Nov 12, 2024EPS Estimate
-$0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.00
Shares Outstanding22,705,994
10 Day Avg. Volume453,492
30 Day Avg. Volume313,310
Standard Deviation0.39
R-Squared0.09
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)-4.04
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.85
Forecast
1Y Price Target
$6.00Price Target Upside450.46% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Iterum Therapeutics News
Bulls Say, Bears Say
Bulls Say
EfficacySulopenem is more effective than many commonly used uUTI antibiotics, including nitrofurantoin, ciprofloxacin, trimethoprim/sulfamethoxazole (TMP/SMX), and cefalexin, many of which also face increasing bacterial resistance.
Market NeedSulopenem could be the first treatment for uUTI patients with a history of infections with organisms producing extended-spectrum beta-lactamase, reducing risks and costs by shifting to an oral therapy.
Potential ApprovalSulopenem could emerge as the first oral penem approved in the US.
Bears Say
Clinical TrialsPrior P3 trials (SURE-1 trial was uUTI) missed on non-inferiority in cipro-susceptible.
Market PerformanceChallenging biotech markets, exacerbated since 2021, have weighed heavily on ITRM shares.
Regulatory ApprovalFailure to secure FDA approval for uUTI and other indications presents a significant risk.
---
Ownership Overview
74.80% Insiders
0.18% Mutual Funds
1.42% Other Institutional Investors
23.60% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ITRM FAQ
What was Iterum Therapeutics Plc’s price range in the past 12 months?
Iterum Therapeutics Plc lowest stock price was $0.62 and its highest was $2.50 in the past 12 months.
What is Iterum Therapeutics Plc’s market cap?
Currently, no data Available
When is Iterum Therapeutics Plc’s upcoming earnings report date?
Iterum Therapeutics Plc’s upcoming earnings report date is Nov 12, 2024 which is in 53 days.
How were Iterum Therapeutics Plc’s earnings last quarter?
Iterum Therapeutics Plc released its earnings results on Aug 14, 2024. The company reported -$0.23 earnings per share for the quarter, beating the consensus estimate of -$0.45 by $0.22.
Is Iterum Therapeutics Plc overvalued?
According to Wall Street analysts Iterum Therapeutics Plc’s price is currently Undervalued.
Does Iterum Therapeutics Plc pay dividends?
Iterum Therapeutics Plc does not currently pay dividends.
What is Iterum Therapeutics Plc’s EPS estimate?
Iterum Therapeutics Plc’s EPS estimate is -$0.18.
How many shares outstanding does Iterum Therapeutics Plc have?
Iterum Therapeutics Plc has 22,705,994 shares outstanding.
What happened to Iterum Therapeutics Plc’s price movement after its last earnings report?
Iterum Therapeutics Plc reported an EPS of -$0.23 in its last earnings report, beating expectations of -$0.45. Following the earnings report the stock price went up 3.419%.
Which hedge fund is a major shareholder of Iterum Therapeutics Plc?
Among the largest hedge funds holding Iterum Therapeutics Plc’s share is New Leaf Venture Partners, L.L.C.. It holds Iterum Therapeutics Plc’s shares valued at 111K.
---
Iterum Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (450.46% Upside)
$6.00 (450.46% Upside)
Hedge Fund Trend
Increased
By 2.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 5.3%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
43.23%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-72.22%
Trailing 12-Months
Company Description
Iterum Therapeutics Plc
Iterum Therapeutics Plc is a clinical-stage pharmaceutical company, which engages in the development and commercialization of treatments for drug resistant bacterial infections. It focuses on sulopenem program that offer a solution to the problem of antibiotic resistance, and the toxicity limitations of existing agents. It operates through the Ireland and Unites States geographical segments. The company was founded by Corey N. Fishman on June 24, 2015 and is headquartered in Dublin, Ireland.
---
ITRM Earnings Call
Q2 2024
0:00 / 0:00
---
ITRM Stock 12 Month Forecast
Average Price Target
$6.00
▲(450.46% Upside)
Technical Analysis
Best Analysts Covering ITRM
1 Year
1 Year Success Rate
1/9 ratings generated profit
1 Year Average Return
-26.83%
reiterated a buy rating 10 days ago
Copying Ed Arce's trades and holding each position for 1 Year would result in 11.11% of your transactions generating a profit, with an average return of -26.83% per trade.
---